Orthofix International N.V. (NASDAQ:OFIX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday. The firm currently has a $54.00 target price on the medical device company’s stock. Zacks Investment Research‘s target price points to a potential upside of 14.04% from the company’s previous close.

According to Zacks, “Orthofix International N.V. is a leading provider of high-value, minimally invasive medical devices for the orthopaedic and trauma markets. Orthofix is well positioned to expand its focus and capitalise on the growing medical acceptance of high technology in orthopaedic treatment and spine repair. The company sells its diverse product line in different countries through its subsidiaries and distribution agreements with leading orthopaedic companies, including Sulzer Medica Group, Sofamor Danek Group, Kendall Healthcare Products and B. Braun. (PRESS RELEASE) “

Other research analysts have also issued reports about the company. BidaskClub lowered Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. SunTrust Banks, Inc. assumed coverage on Orthofix International N.V. in a report on Tuesday, May 23rd. They set a “buy” rating and a $49.00 target price on the stock. Ladenburg Thalmann Financial Services assumed coverage on Orthofix International N.V. in a report on Wednesday, June 14th. They set a “buy” rating and a $53.25 target price on the stock. BTIG Research assumed coverage on Orthofix International N.V. in a report on Wednesday, June 21st. They set a “buy” rating and a $52.00 target price on the stock. Finally, Langenberg & Company reaffirmed a “buy” rating and set a $53.25 target price on shares of Orthofix International N.V. in a report on Wednesday, June 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Orthofix International N.V. has an average rating of “Buy” and an average target price of $52.30.

Orthofix International N.V. (NASDAQ OFIX) opened at 47.35 on Thursday. Orthofix International N.V. has a 1-year low of $32.51 and a 1-year high of $48.55. The firm’s market capitalization is $854.38 million. The stock’s 50 day moving average is $45.44 and its 200-day moving average is $40.49.

Orthofix International N.V. (NASDAQ:OFIX) last released its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The firm had revenue of $108.90 million for the quarter, compared to analyst estimates of $102.94 million. Orthofix International N.V. had a return on equity of 10.04% and a net margin of 1.88%. Orthofix International N.V.’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 earnings per share. Equities research analysts forecast that Orthofix International N.V. will post $1.55 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/10/orthofix-international-n-v-ofix-lifted-to-buy-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OFIX. Arizona State Retirement System raised its position in Orthofix International N.V. by 1.1% in the second quarter. Arizona State Retirement System now owns 9,400 shares of the medical device company’s stock worth $437,000 after buying an additional 100 shares during the last quarter. Systematic Financial Management LP raised its position in Orthofix International N.V. by 0.6% in the first quarter. Systematic Financial Management LP now owns 44,310 shares of the medical device company’s stock worth $1,690,000 after buying an additional 260 shares during the period. Victory Capital Management Inc. raised its position in Orthofix International N.V. by 1.2% in the second quarter. Victory Capital Management Inc. now owns 32,089 shares of the medical device company’s stock worth $1,491,000 after buying an additional 365 shares during the period. American International Group Inc. raised its position in Orthofix International N.V. by 7.1% in the first quarter. American International Group Inc. now owns 10,783 shares of the medical device company’s stock worth $411,000 after buying an additional 717 shares during the period. Finally, Gabelli Funds LLC raised its position in Orthofix International N.V. by 0.3% in the first quarter. Gabelli Funds LLC now owns 291,450 shares of the medical device company’s stock worth $11,119,000 after buying an additional 1,000 shares during the period. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

About Orthofix International N.V.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get a free copy of the Zacks research report on Orthofix International N.V. (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.